← All trials
NCT04514419
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2020
- Primary completion
- Nov 20, 2021
- Completion date
- Nov 20, 2021
- First posted
- Aug 17, 2020
- Last posted
- Aug 17, 2020
- Enrollment
- 408
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Zhejiang Hisun Pharmaceutical Co. Ltd.Lead sponsor
- Qingdao UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.